Comparative Pharmacology
Head-to-head clinical analysis: VIMIZIM versus VPRIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIMIZIM versus VPRIV.
VIMIZIM vs VPRIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VIMIZIM (elosulfase alfa) is a recombinant human N-acetylgalactosamine-6-sulfatase that hydrolyzes the sulfate ester bond at position 6 of N-acetylgalactosamine in chondroitin sulfate and keratan sulfate, thereby reducing glycosaminoglycan (GAG) accumulation in patients with Morquio A syndrome (mucopolysaccharidosis IVA).
VPRIV (velaglucerase alfa) is a recombinant form of human lysosomal glucocerebrosidase that hydrolyzes glucocerebroside to glucose and ceramide, replacing the deficient enzyme in Gaucher disease.
2 mg/kg administered intravenously once weekly over approximately 4 hours. Pretreat with antihistamines and antipyretics 30-60 minutes prior to infusion.
60 U/kg intravenously every 2 weeks over 4 hours.
None Documented
None Documented
Terminal elimination half-life approximately 9.8 days (range 7.7–13.8 days) in patients with mucopolysaccharidosis VI (MPS VI). Long half-life supports weekly intravenous dosing.
Terminal elimination half-life is approximately 30 minutes (range 15-60 minutes) in Gaucher disease patients, necessitating intravenous infusion over 1-2 hours every other week.
Primarily renal. No specific data on biliary or fecal elimination; as a recombinant enzyme, likely catabolized to peptides and amino acids, with renal excretion of metabolites.
Primarily metabolized via peptide hydrolysis; elimination is predominantly non-renal. Renal excretion accounts for <5% of the dose as intact drug. Fecal elimination of metabolites is negligible.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy